View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Novartis AG: 1 director

A director at Novartis AG sold 55,000 shares at 90.477CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Luis de Toledo Heras
  • Luis de Toledo Heras

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/23/2024

In the run-up to the 2024 Summer Olympic Games and Euro 2024 football tournament, we have identified six stocks to favour: JCDecaux, Accor, Sodexo, adidas, Unibail-Rodamco-Westfield and easyJet. While these two major sporting events are not expected to have a significant impact on the host economies in the medium term, the microeconomic and sectoral impacts should be more marked. The tourism, transport, beverages and consumer goods sectors are expected to be the main winners. Some med...

Luis de Toledo Heras
  • Luis de Toledo Heras

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 23/04/2024

En amont des Jeux Olympiques d’été et de l’Euro de football 2024, nous identifions 6 valeurs à privilégier  : JCDecaux, Accor, Sodexo, adidas, Unibail-Rodamco-Westfield et easyJet. Alors que ces deux évènements sportifs majeurs ne devraient pas avoir d’impact significatif sur les économies hôtes à moyen terme, les impacts microéconomiques et sectoriels devraient être plus marqués. Les secteurs du tourisme, des transports, des boissons et des biens de consommation devraient être les pr...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Novartis : Excellent Q1 results that justify an increase in the full-y...

>Q1 beats expectations for the top line (+4%) and bottom line (+7%) - Q1 came in ahead of expectations for sales (+4% vs consensus) and core EPS (+7% vs consensus). Sales grew 11% at CER (10% reported), driven by all the flagship products: Entresto (growth of 34%, +15% vs consensus), Cosentyx (23%, 10% vs cons.), Kisqali (51%, -2% vs cons.) and Kesimpta (66%, 0% vs cons.). Note that Pluvicto (47%, -3% vs cons.) once again undershot expectations and our estimates slig...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Novartis : Excellent T1 justifiant un relèvement de guidance FY

>T1 au-dessus des attentes sur la topline (+4%) et la bottom line (+7%) - Le T1 ressort au-dessus des attentes au niveau des ventes (+4% vs Css) et du core BPA (+7% vs Css). Les ventes progressent de 11% tcc (10% en publié) tirées par tous les produits phares : Entresto (34%, +15% vs Css), Cosentyx (23%, 10% vs Css), Kisqali (51%, -2% vs Css) et Kesimpta (66%, 0% vs Css). Notons que Pluvicto (47%, -3% vs Css) ressort une nouvelle fois légèrement en dessous des attente...

Oliver Metzger
  • Oliver Metzger

ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024

Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...

Oliver Metzger
  • Oliver Metzger

ODDO BHF Small & MIDCAP MORNING NEWS - 11/04/2024

Waga Energy propose un profil de start-up innovante dans le secteur des utilities : i/ une technologie disruptive pour le traitement du biogaz, ii/ des avantages compétitifs établis, iii/ un positionnement sur un marché à fort potentiel (>20 000 décharges) et iv/ un modèle robuste de revenus récurrents. La société a reconfirmé lors du CMD en février 2024 ses ambitions à horizon 2026 annoncées au moment de son IPO (signature de 4 TWh et CA récurrent de 200 M€). Fort des financements ob...

Team Pharma
  • Team Pharma

ODDO : Q1 2024 will not set the tone for the year

>Renewed interest in the sector on the stock market since the start of the year - After a challenging end to the year for the pharma sector in 2023, it has picked up since the start of the year (our coverage +15% vs Stoxx 600 +7%). Novo Nordisk continues to be the driver (+26% in Q1) aided by the re-rating of GSK (+18%). Novartis has also contributed, albeit to a lesser extent, with a gain of 3% in Q1. Sanofi, AstraZeneca and Roche bring up the rear, with gains of 1% ...

Team Pharma
  • Team Pharma

ODDO : Le T1 2024 ne donnera pas le ton de l’année

>Un regain d’intérêt pour le secteur en Bourse depuis le début de l’année - Après une fin d’année difficile pour le secteur, la pharma a repris des couleurs depuis le début d’année (coverage +15% vs Stoxx 600 +7%). Novo Nordisk continue de jouer son rôle de locomotive (+26% lors du T1) aidé par le rerating de GSK (+18%). Dans une moindre mesure, Novartis affiche une performance de 3% lors de ce T1. Sanofi, AstraZeneca et Roche ressortent en queue de peloton à 1%, +0.7...

Wedbush Research
  • Wedbush Research
2454 MEDIATEK INC.
MTB M&T BANK CORPORATION
VMW VMWARE INC. CLASS A
BLUE BLUEBIRD BIO INC.
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WDC WESTERN DIGITAL CORPORATION
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VYGR VOYAGER THERAPEUTICS INC.
VLY VALLEY NATIONAL BANCORP
TCBI TEXAS CAPITAL BANCSHARES INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RGNX REGENXBIO INC.
RF REGIONS FINANCIAL CORPORATION
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
PAYX PAYCHEX INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
KEY KEYCORP
INTC INTEL CORPORATION
HMST HOMESTREET INC.
HBI HANESBRANDS INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
GOOGL ALPHABET INC. CLASS A
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
COLB COLUMBIA BANKING SYSTEM INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
BMRN BIOMARIN PHARMACEUTICAL INC.
BKU BANKUNITED INC.
BIIB BIOGEN INC.
BANC BANC OF CALIFORNIA INCORPORATED
AXTI AXT INC.
NFLX NETFLIX INC.
CFR CULLEN/FROST BANKERS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
SLM SLM CORP
HPE HEWLETT PACKARD ENTERPRISE CO.
NTLA INTELLIA THERAPEUTICS INC.
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
ROKU ROKU INC. CLASS A
VRNA VERONA PHARMA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
AX AXOS FINANCIAL INC.
DELL DELL TECHNOLOGIES INC CLASS C
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
PASG INC.
BEAM PASSAGE BIO
GBIO BEAM THERAPEUTICS
FUBO GENERATION BIO
BUR FUBOTV
FHTX BURFORD CAPITAL
MRVL FOGHORN THERAPEUTICS
STX MARVELL TECHNOLOGY INC
TSVT SEAGATE TECHNOLOGY HLDGS PLC
DSGN 2SEVENTY BIO INC
GFS DESIGN THERAPEUTICS INC
PEPG GLOBALFOUNDRIES INC
BROS PEPGEN INC
PRME DUTCH BROS INC
PRIME MEDICINE INC
David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

Amgen Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Near-term focus on pipeline execution, integration of Hori...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by unresolved IRS tax disputes

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch